| abstract |
This disclosure relates to oligonucleotides, compositions and methods useful for reducing CYP27A1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of CYP27A1 expression may be double-stranded or single-stranded and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of CYP27A1 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat hepatobiliary disease and related conditions (e.g., liver fibrosis). |